176 related articles for article (PubMed ID: 10778993)
1. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.
Fanciulli M; Bruno T; Giovannelli A; Gentile FP; Di Padova M; Rubiu O; Floridi A
Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993
[TBL] [Abstract][Full Text] [Related]
2. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A
Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807
[TBL] [Abstract][Full Text] [Related]
3. Correspondence re: M. Fanciulli et al., Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence fo lonidamine. Clin. Cancer Res., 6: 1590-1597, 2000.
Kaplan O
Clin Cancer Res; 2000 Oct; 6(10):4166-7. PubMed ID: 11051272
[No Abstract] [Full Text] [Related]
4. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells.
Fanciulli M; Bruno T; Castiglione S; Del Carlo C; Paggi MG; Floridi A
Oncol Res; 1993; 5(9):357-62. PubMed ID: 8038456
[TBL] [Abstract][Full Text] [Related]
5. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
6. Intracellular P-glycoprotein in multidrug resistant tumor cells.
Arancia G; Molinari A; Calcabrini A; Meschini S; Cianfriglia M
Ital J Anat Embryol; 2001; 106(2 Suppl 1):59-68. PubMed ID: 11729998
[TBL] [Abstract][Full Text] [Related]
7. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.
Yang LY; Trujillo JM
Cancer Res; 1990 Jun; 50(11):3218-25. PubMed ID: 2334917
[TBL] [Abstract][Full Text] [Related]
8. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A
Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982
[TBL] [Abstract][Full Text] [Related]
9. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells.
Bartolini G; Orlandi M; Papi A; Ammar K; Guerra F; Ferreri AM; Rocchi P
In Vivo; 2006; 20(6A):729-33. PubMed ID: 17203756
[TBL] [Abstract][Full Text] [Related]
10. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells.
Miccadei S; Fanciulli M; Bruno T; Paggi MG; Floridi A
Oncol Res; 1996; 8(1):27-35. PubMed ID: 8704284
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between multidrug resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration].
Ma Q; Zhang ZS; Zhang YL; Lai ZS
Ai Zheng; 2002 Aug; 21(8):846-9. PubMed ID: 12478890
[TBL] [Abstract][Full Text] [Related]
12. Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells.
Scala S; Pacelli R; Iaffaioli RV; Normanno N; Pepe S; Frasci G; Genua G; Tsuruo T; Tagliaferri P; Bianco AR
Cancer Res; 1991 Sep; 51(18):4898-902. PubMed ID: 1893380
[TBL] [Abstract][Full Text] [Related]
13. Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells.
Yang LY; Trujillo JM; Su YZ
Anticancer Res; 1992; 12(2):473-9. PubMed ID: 1349796
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism.
Floridi A; Bruno T; Miccadei S; Fanciulli M; Federico A; Paggi MG
Biochem Pharmacol; 1998 Oct; 56(7):841-9. PubMed ID: 9774146
[TBL] [Abstract][Full Text] [Related]
15. Mitochondria, hexokinase and pyruvate kinase isozymes in the aerobic glycolysis of tumor cells.
Petrucci D; Cesare P; Colafarina S
Ital J Biochem; 1997 Sep; 46(3):131-41. PubMed ID: 9442422
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
17. [Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line].
Fuchs AG
Medicina (B Aires); 2008; 68(1):13-22. PubMed ID: 18416315
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition by rhein and lonidamine of human glioma cells in vitro.
Floridi A; Gentile FP; Bruno T; Castiglione S; Zeuli M; Benassi M
Anticancer Res; 1990; 10(6):1633-6. PubMed ID: 2285235
[TBL] [Abstract][Full Text] [Related]
19. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
20. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
